Effectiveness of Oseltamivir in Preventing Influenza in Household Contacts: A Randomized Controlled Trial | Geriatrics | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.212.130. Please contact the publisher to request reinstatement.
1.
 Human influenza In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza . Oxford, England: Blackwell Science; 1998:219-264.
2.
Stuart-Harris CH, Schild GC, Oxford JS. Influenza: The Viruses and the Disease. 2nd ed. London, England: Edward Arnold; 1985:264.
3.
Foy HM, Cooney MK, Allen I. Longitudinal studies of types A and B influenza among Seattle school children and families, 1968-1974.  J Infect Dis.1976;134:362-369.Google Scholar
4.
Fox JP, Hall CE, Cooney MK, Foy HM. Influenza virus infections in Seattle families, 1975-1979.  Am J Epidemiol.1982;116:212-242.Google Scholar
5.
Taber LH, Paredes A, Glezen WP, Couch RB. Infection with influenza A/Victoria virus in Houston families, 1976.  J Hyg (Lond).1981;86:303-313.Google Scholar
6.
Longini IM, Koopman JS, Monto AS, Fox JP. Estimating household and community transmission parameters for influenza.  Am J Epidemiol.1982;115:736-751.Google Scholar
7.
Clover RD, Crawford SA, Abell TD, Ramsey Jr CN, Glezen WP, Couch RB. Effectiveness of rimantadine prophylaxis of children within families.  Am J Dis Child.1986;140:706-709.Google Scholar
8.
Galbraith AW, Oxford JS, Schild GC, Watson GI. Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family.  Bull World Health Organ.1969;41:677-682.Google Scholar
9.
Galbraith AW, Oxford JS, Schild GC, Watson GI. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study.  Lancet.1969;2:1026-1028.Google Scholar
10.
Degelau J, Somani SK, Cooper SL, Guay DR, Crossley KB. Amantadine-resistant influenza A in a nursing facility.  Arch Intern Med.1992;152:390-392.Google Scholar
11.
Hayden FG, Gwaltney Jr JM, van de Castle RL, Adams KF, Giordani B. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults.  Antimicrob Agents Chemother.1981;19:226-233.Google Scholar
12.
Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.  N Engl J Med.1989;321:1696-1702.Google Scholar
13.
Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.  Antimicrob Agents Chemother.1991;35:1741-1747.Google Scholar
14.
Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors.  Lancet.2000;355:827-835.Google Scholar
15.
Kim CU, Lew W, Williams MA.  et al.  Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.  J Am Chem Soc.1997;119:681-690.Google Scholar
16.
Treanor JJ, Hayden FG, Vrooman PS.  et al.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial.  JAMA.2000;283:1016-1024.Google Scholar
17.
Mendel DB, Tai CY, Escarpe PA.  et al.  Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection.  Antimicrob Agents Chemother.1998;42:640-646.Google Scholar
18.
Sidwell RW, Huffman JH, Barnard DL.  et al.  Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.  Antiviral Res.1998;37:107-120.Google Scholar
19.
Hayden FG, Treanor JJ, Fritz RS.  et al.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.  JAMA.1999;282:1240-1246.Google Scholar
20.
Hayden FG, Atmar RL, Schilling M.  et al.  Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.  N Engl J Med.1999;341:1336-1343.Google Scholar
21.
 World Medical Association Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects.  JAMA1997;277:925-926.Google Scholar
22.
Wilson LA, Brass W. Brief assessment of the mental state in geriatric domiciliary practice: the usefulness of the Mental Status Questionnaire.  Age Ageing.1973;2:92-101.Google Scholar
23.
Donner A. Some aspects of the design and analysis of cluster randomization trials.  Appl Stat.1998;47:95-113.Google Scholar
24.
De Bock V, Peters P, von Planta T-A.  et al.  Oral oseltamivir for prevention of influenza in the frail elderly.  Clin Microbiol Infect.2000;6(suppl 1):140.Google Scholar
25.
Gubareva LV, Matrosovich MN, Brenner MK.  et al.  Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.  J Infect Dis.1998;178:1257-1262.Google Scholar
26.
Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine.  Curr Top Microbiol Immunol.1992;176:119-130.Google Scholar
27.
Covington E, Mendel DB, Escarpe P.  et al.  Phenotypic and genotypic assay of influenza virus neuraminidase indicates a low incidence of viral drug resistance during treatment with oseltamivir [abstract P-326].  J Clin Virol.2000;18:253.Google Scholar
28.
Hayden FG, Gubareva LV, Monto AS.  et al.  Inhaled zanamivir for the prevention of influenza in families.  N Engl J Med.2000;343:1282-1289.Google Scholar
29.
Hurwitz ES, Haber M, Chang A.  et al.  Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts.  JAMA.2000;284:1677-1682.Google Scholar
30.
Whitley RJ, Hayden FG, Reisinger KS.  et al.  Oral oseltamivir treatment of influenza in children.  Pediatr Infect Dis J.In press.Google Scholar
Original Contribution
February 14, 2001

Effectiveness of Oseltamivir in Preventing Influenza in Household Contacts: A Randomized Controlled Trial

Author Affiliations

Author Affiliations: Children's Hospital, Buffalo, NY (Dr Welliver); University of Michigan School of Public Health, Ann Arbor (Dr Monto); Comprehensive Clinical Research, Berlin, NJ (Dr Hassman); Kentucky Pediatric and Adult Research, Bardstown, Ky (Dr Hedrick); Roche Global Development, Welwyn, England (Drs Jackson, Huson, and Ward); and St Bartholomew's and Royal London Hospital School of Medicine and Dentistry, and Retroscreen Virology Ltd, London, England (Dr Oxford). Dr Carewicz is in private practice in Heidelberg, Germany, and Dr Schatteman is in private practice in Drogen, Ghent, Belgium.

JAMA. 2001;285(6):748-754. doi:10.1001/jama.285.6.748
Abstract

Context Influenza virus is easily spread among the household contacts of an infected person, and prevention of influenza in household contacts can control spread of influenza in the community.

Objective To investigate the efficacy of oseltamivir in preventing spread of influenza to household contacts of influenza-infected index cases (ICs).

Design and Setting Randomized, double-blind, placebo-controlled study conducted at 76 centers in North America and Europe during the winter of 1998-1999.

Participants Three hundred seventy-seven ICs, 163 (43%) of whom had laboratory-confirmed influenza infection, and 955 household contacts (aged ≥12 years) of all ICs (415 contacts of influenza-positive ICs).

Interventions Household contacts were randomly assigned by household cluster to take 75 mg of oseltamivir (n = 493) or placebo (n = 462) once daily for 7 days within 48 hours of symptom onset in the IC. The ICs did not receive antiviral treatment.

Main Outcome Measure Clinical influenza in contacts of influenza-positive ICs, confirmed in a laboratory by detection of virus shedding in nose and throat swabs or a 4-fold or greater increase in influenza-specific serum antibody titer between baseline and convalescent serum samples.

Results In contacts of an influenza-positive IC, the overall protective efficacy of oseltamivir against clinical influenza was 89% for individuals (95% confidence interval [CI], 67%-97%; P<.001) and 84% for households (95% CI, 49%-95%; P<.001). In contacts of all ICs, oseltamivir also significantly reduced incidence of clinical influenza, with 89% protective efficacy (95% CI, 71%-96%; P<.001). Viral shedding was inhibited in contacts taking oseltamivir, with 84% protective efficacy (95% CI, 57%-95%; P<.001). All virus isolates from oseltamivir recipients retained sensitivity to the active metabolite. Oseltamivir was well tolerated; gastrointestinal tract effects were reported with similar frequency in oseltamivir (9.3%) and placebo (7.2%) recipients.

Conclusion In our sample, postexposure prophylaxis with oseltamivir, 75 mg once daily for 7 days, protected close contacts of influenza-infected persons against influenza illness, prevented outbreaks within households, and was well tolerated.

×